Similarly, some studies focused on the use of drugs structurally similar to KYN to modify the progression of MS, given the close relationship between some intermediates of the KP and factors such as NF-kβ, PPARγ and PGC-1 involved in the inflammatory response [151]. Here, PPARGC1A is linked to myeloid sarcoma.